{"ticker": {"uuid": "3fc99a3c-04f9-4c33-b6a9-089acfa9525f", "symbol": "PEPG", "name": "PepGen Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PEPG - PepGen Inc Latest SEC Filings", "summary": "This page provides the latest SEC filings for PepGen Inc. (PEPG), along with a comprehensive overview of its financial performance, stock statistics, and trading data. It includes key metrics such as market capitalization, income, sales, EPS, insider and institutional ownership, ", "url": "https://finviz.com/stock?t=PEPG&p=m&ty=lf&b=2&r=max&page=2", "source_name": "Finviz", "published_at": "2026-07-04T19:10:29", "published_display": "04 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPG LAWSUIT ALERT: Levi & Korsinsky Notifies PepGen Inc. Investors - Lead Plaintiff Deadline August 8, 2025", "summary": "Levi & Korsinsky LLP has issued a lawsuit alert for investors of PepGen Inc. (NASDAQ: PEPG) who suffered losses. The class action securities lawsuit alleges that PepGen made false statements regarding the effectiveness and safety of its lead product candidate, PGN-EDO51, and its ", "url": "https://www.natlawreview.com/press-releases/pepg-lawsuit-alert-levi-korsinsky-notifies-pepgen-inc-investors-lead", "source_name": "The National Law Review", "published_at": "2026-07-03T05:39:57", "published_display": "03 Jul 2026 05:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages PepGen Inc. (PEPG) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of PepGen Inc. (PEPG) investors who purchased securities prior to March 7, 2024, and continue to hold them. The investigation aims to determine if PepGen and its officers/directors engaged in corporate", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-pepgen-inc-pepg-investors-inquire", "source_name": "The National Law Review", "published_at": "2026-07-02T07:40:51", "published_display": "02 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PepGen Inc. \u2013 NASDAQ:PEPG", "summary": "This page from TradingView provides financial information for PepGen Inc. (NASDAQ: PEPG), specifically focusing on its \"Price to book forward\" metric. It appears to be an empty or placeholder financial data point for the specified period.", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T09:12:32", "published_display": "01 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by PepGen Inc. (NASDAQ: PEPG). The firm encourages shareholders who purchased PepGen securities before March 7, 2024, and still hold them, to contact them to learn more and potent", "url": "https://natlawreview.com/press-releases/pepgen-inc-pepg-investigation-bronstein-gewirtz-grossman-llc-encourages-0", "source_name": "The National Law Review", "published_at": "2026-06-29T16:39:45", "published_display": "29 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of PepGen Inc. \u2013 NASDAQ:PEPG", "summary": "This article displays the Enterprise Value to EBIT forward for PepGen Inc. (NASDAQ: PEPG). The content primarily consists of navigation and boilerplate information from the TradingView platform, with the specific financial data point \"Enterprise value to EBIT forward\" listed for ", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T17:10:19", "published_display": "28 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating PepGen Inc. (PEPG) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against PepGen Inc. (PEPG) for alleged corporate wrongdoing. The investigation encourages stockholders who purchased PepGen securities before March 7, 2024, and still hold them, to contact the firm to assist wit", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-pepgen-inc-pepg-and-encourages", "source_name": "The National Law Review", "published_at": "2026-06-28T16:39:02", "published_display": "28 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed: PepGen Inc. (PEPG) - Join by August 8, 2025 - Contact Levi & Korsinsky", "summary": "A class action lawsuit has been filed against PepGen Inc. (NASDAQ:PEPG) alleging securities fraud between March 7, 2024, and March 3, 2025. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky, LLP by August 8, 2025, to learn about their ", "url": "https://www.natlawreview.com/press-releases/class-action-lawsuit-filed-pepgen-inc-pepg-join-august-8-2025-contact-levi", "source_name": "The National Law Review", "published_at": "2026-06-28T04:10:38", "published_display": "28 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PepGen Inc. \u2013 NASDAQ:PEPG", "summary": "The article focuses on the \"Price to sales forward\" metric for PepGen Inc. (NASDAQ: PEPG). It indicates that the financial data is provided by ICE Data Services and FactSet Research Systems Inc., with SEC filings by Quartr. The content appears to be a financial data point within ", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:10:26", "published_display": "28 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PepGen Inc. \u2013 BOATS:PEPG", "summary": "This article provides financial information for PepGen Inc. (PEPG) on the Blue Ocean Alternative Trade System (BOATS). It specifically focuses on the company's price to earnings forward ratio, indicating financial data for the period, value, change, and change percentage.", "url": "https://www.tradingview.com/symbols/BOATS-PEPG/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T01:09:26", "published_display": "28 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPG SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against PepGen Inc. (NASDAQ: PEPG). The lawsuit alleges that PepGen and its officers made false and misleading statements about the effectiveness and safety of PGN-EDO51 and the CONNECT2 study, which overstat", "url": "https://natlawreview.com/press-releases/pepg-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-pepgen-1", "source_name": "The National Law Review", "published_at": "2026-06-27T15:10:26", "published_display": "27 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did You Lose Money on PepGen Inc. (PEPG)? Levi & Korsinsky Urges Investors to Act Before August 8, 2025", "summary": "Levi & Korsinsky LLP is urging investors of PepGen Inc. (PEPG) who suffered losses to act before August 8, 2025, to potentially recover losses through a class action securities lawsuit. The lawsuit alleges that PepGen made false statements regarding its lead product candidate, PG", "url": "https://natlawreview.com/press-releases/did-you-lose-money-pepgen-inc-pepg-levi-korsinsky-urges-investors-act-august", "source_name": "The National Law Review", "published_at": "2026-06-27T14:09:26", "published_display": "27 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of PepGen Inc. \u2013 NASDAQ:PEPG", "summary": "This article focuses on shareholder information for PepGen Inc. (NASDAQ: PEPG). It provides access to financial data, news, documents, and community discussions related to the company on the TradingView platform. Users can find details about the number of shareholders over differ", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-27T11:38:42", "published_display": "27 Jun 2026 11:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PepGen Inc. \u2013 BOATS:PEPG", "summary": "This article provides the forward price-to-sales ratio for PepGen Inc. (PEPG). It presents a financial data point for the company and is hosted on TradingView, a financial charting and analysis platform.", "url": "https://www.tradingview.com/symbols/BOATS-PEPG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:38:42", "published_display": "27 Jun 2026 10:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc. Actuals & Estimates (NASDAQ:PEPG)", "summary": "This article provides an overview of PepGen Inc. (NASDAQ:PEPG) financial actuals and estimates, including its current stock price, historical performance, analyst forecasts, and company financials. It details the company's stock volatility, market capitalization, earnings per sha", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:09", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for PepGen Inc. (PEPG), based on analyst opinions. It includes current stock performance, historical highs and lows, volatility, market capitalization, and details on earnings and revenue. The report also addresses frequently aske", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:23", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) director granted 34,000 options for RA Capital funds", "summary": "PepGen Inc. director Joshua Resnick was granted 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. These options are held for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account, with Resnic", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-c4c5164d10fc.html", "source_name": "Stock Titan", "published_at": "2026-06-23T15:10:26", "published_display": "23 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) awards director 34,000 options vesting by next meeting", "summary": "PepGen Inc. (PEPG) reported that director Lisa Wyman received a grant of 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. These options will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-73a63580950b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T13:40:23", "published_display": "23 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "34K PepGen (PEPG) options awarded for RA Capital-managed accounts", "summary": "PepGen Inc. reported a compensation-related transaction where an option to purchase 34,000 shares of common stock was awarded to Dr. Resnick, a director, for the benefit of RA Capital-managed entities. The option has an exercise price of $1.79 per share and vests fully upon the e", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-805a19cec65f.html", "source_name": "Stock Titan", "published_at": "2026-06-23T03:09:26", "published_display": "23 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen director granted options for 34,000 shares | PEPG Insider Trading", "summary": "PepGen Inc. director Laurie Keating was granted stock options for 34,000 shares at an exercise price of $1.79 per share, expiring on June 17, 2036. The options will vest fully on the earlier of the first anniversary of the grant date or the next Annual Meeting, provided she conti", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-231dc1448654.html", "source_name": "Stock Titan", "published_at": "2026-06-23T01:09:13", "published_display": "23 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) director receives 34,000 stock options at $1.79 strike", "summary": "PepGen Inc. director Mitchell H. Finer was granted 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. The options vest fully on the earlier of the first anniversary of the grant date or the next Annual Meeting, provided he continues to serv", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-7a427c8d17ea.html", "source_name": "Stock Titan", "published_at": "2026-06-23T01:09:13", "published_display": "23 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) loses 14.3% in 4 weeks, here's why a trend reversal may be around the corner", "summary": "The article suggests PepGen (PEPG) stock, which has fallen 14.3% in the last four weeks, might be due for a trend reversal. This potential shift is based on the company's strong fundamentals and the stock's current oversold condition, as indicated by its 10-day moving average and", "url": "http://www.msn.com/en-us/money/top-stocks/pepgen-pepg-loses-14-3-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner/ar-AA23F6Wo?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-23T00:40:38", "published_display": "23 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 PepGen Ltd For: 22 June By Investing.com", "summary": "This article announces the filing of Form 4 for PepGen Ltd. on June 22 and provides a link to view the filing. It also includes general market data and related news without further details on the specific Form 4 content.", "url": "https://ng.investing.com/news/stock-market-news/form-4-pepgen-ltd-for-22-june-93CH-2568525", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T21:10:00", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) investors elect Class I directors and ratify KPMG as 2026 auditor", "summary": "PepGen Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026, where shareholders elected three Class I directors: Howard Mayer, M.D., Joshua Resnick, M.D., M.B.A., and Lisa Wyman, M.S. These directors will serve until the 2029 annual meeting. Shareholders also ratifi", "url": "https://www.stocktitan.net/sec-filings/PEPG/8-k-pep-gen-inc-reports-material-event-37f2b5748084.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:49", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) director Howard Mayer awarded options on 34,000 shares", "summary": "PepGen Inc. director Howard Mayer was granted 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. This grant is part of his compensation and vests fully on the earlier of the first anniversary of the grant date or the next annual meeting, pr", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-1f8837eb19c2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:49", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) director receives 34,000 stock options grant", "summary": "PepGen Inc. director Heidi Henson was granted 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. These options will vest fully on the earlier of the first anniversary of the grant date or the next Annual Meeting, subject to her continued se", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-3653eeff10c0.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:39:49", "published_display": "22 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc (PEPG) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of PepGen Inc (PEPG), identifying major individual shareholders like RA Capital Management, LP and Oxford Science Enterprises PLC, along with their respective proportions. It also categorizes shareholders by type, such as venture cap", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pepg/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:05", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc (PEPG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for PepGen Inc (PEPG), highlighting analyst ratings, target prices, and revenue growth estimates. Seven analysts currently rate the stock as \"Buy,\" with a target price of $9.00 and an upside potential of 537.92%. The article also reviews", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pepg/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:05", "published_display": "18 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum initiates PepGen stock coverage with buy rating By Investing.com", "summary": "Craig-Hallum has initiated coverage on PepGen Inc. (NASDAQ:PEPG) with a buy rating and an $11.00 price target, noting a substantial upside potential from its current trading price of $1.64. The firm sees PepGen's lead drug candidate, PGN-EDODM1, as a high-risk but highly asymmetr", "url": "https://za.investing.com/news/stock-market-news/craighallum-initiates-pepgen-stock-coverage-with-buy-rating-93CH-4330937", "source_name": "Investing.com South Africa", "published_at": "2026-06-17T12:13:15", "published_display": "17 Jun 2026 12:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Initiates PepGen at Buy With $11 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/craig-hallum-initiates-pepgen-buy-112120380.html", "source_name": "MT Newswires", "published_at": "2026-06-16T11:21:20+00:00", "published_display": "16 Jun 2026 11:21", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] PepGen Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPcllrU0NLdmhYaXhoUjhXMEZYTmlJSThScXJHc1JkbGFFSk1tZmVIVTA1OGN3ajVfSW1FdVdqclFMV05zMXJIZ0Uxa0FBOGhfQXMxZ3d3eG83YWw4aERKWHdBRjdVTmZ5R0ZsSTF1LUM2NWtrZHQ2YTUwOU1CT19NYnJneERjdDc2R09DVlVZeS1WVVNWdXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Files $400 Million Mixed Shelf", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pepgen-files-400-million-mixed-162328424.html", "source_name": "MT Newswires", "published_at": "2026-05-19T16:23:28+00:00", "published_display": "19 May 2026 16:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPT2c3djRxN1oyeW85V0hCN2JJS0h4UW9pd3ZSa3AzS2xyUG04SkQ2M2FHTktuVVVlREN6Z1BUMXJRN0lrWmVtQW5LOTNWVzZWY1FzU2lXLU00SUl2a25nbjRMOXhib2lYSEc0ZmJpZFVrVmt5QkpnQ0JxWHdvdkI1YkoxZWhpMHhmeXdHbGdDel9RTlYzMzhN?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PepGen (PEPG) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/news/pepgen-pepg-upgraded-buy-heres-160004314.html", "source_name": "Zacks", "published_at": "2026-05-13T16:00:04+00:00", "published_display": "13 May 2026 16:00", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Trims Price Target on PepGen to $4 From $5, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/news/wedbush-trims-price-target-pepgen-132631278.html", "source_name": "MT Newswires", "published_at": "2026-05-13T13:26:31+00:00", "published_display": "13 May 2026 13:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPVGZHaHJGVHZLa1RoMHByRFlJZHFnNHZ6QzRrMWFURUZZWC10QXlXWTlNc0RPUGVGWXZOSkZqWlV0M2JDMkR0dUJVVUlOVm52N0pGaEZWMWVTMUJ5Ulh1ckt3QTlrVkdZU19MaHlnc0RpSFhSUE52azY3bEp5NDRGRmdIM3k2Wm55TlBZT1UtTERqaHpPb1YtSjl5aEgycW5ZMlhRRzREZFhCdTNtckwwY1M4TXJ2SXRPWkRVMUZXd044MTI4VU1zUkJwT1BxcEZMU0QyOFR2ZjZjdFFlSV8yazRmR1ZTQTBN?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At PepGen (PEPG) Valuation After FREEDOM2 Phase 2 Topline Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQOUhEOFRqdjlfYU1aZ0plVm9xd2tSd0ZsTXJjZnp0YVUxR3VUQzBZRE95eG9EQnlkUDg4U0VERVRGM1NjVkc5NFJ5Y0JJczI0RXJQdHBHOGZaRkwwa01nZHlBVTUtSU5VWnJ1alg4c3ZkN3NEeUN2LTNnVkhPWmlqX3pxNzlPbmVISWwzMUFkNnhzTnNYWTN4NFg3TVNzLTRCSHhTNFFLWmNGV2ZjVEdLOWVRbzB1Znhr?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc. Shareholders Are Encouraged to Reach Out to", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxNZlZnaDVsQ1owbmQzcGpkdGtrVDROSFJmVWhSa0xGSUNMdzMteHFObXdOLUlmVHdrSlJmbXp1QXlaWGMtOU1SS0NST0w4aXppQllHR2hfYzNjVXB5ekVLdlU4MWhxaEJSbUMxal92YzhxeVBxYzBVb2lxMFFkTGowZUdqRGVHSGVjZmpYbEhaNUpBcjhVUGZPeE5ELXFPRzZJU1BIQ2xrM2FvVW96YXhwOG9YZ3N2QTh3SmItQk1xNnV1ZGxmOGJXS1ZKdUVSUDhUVGhjVHltR3dxMmlnamRyMDItcFZjX0NibkpQUFVtSm9GZUtxc3hJTWRZWlJHaFFhOEhlWUpISElPcXNQUlhITjE3b2tRNjlQakZaRWNqNXkyeWRJS3RvU2t0cw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQbzNUVFBsMk9odF9DWUpQTi0zUDNqNnFTa0FuZXNGdXBVUGhZVTZLX014NDFBWEJaRkJQY1hmSldFZWVGUkVQei02dGp6ajZJV2d2Q21hR0MzenlmWTFkWjI2WXh5Z25IWXp4anZmZW9nQmJTNHFsM3Vxd190R2dqOHJpaTkzbVQySEE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In an 8-patient muscle disease study, PepGen saw no serious safety issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOdGxTN1Bwc0Q0WHlyRk41Z1hZNnpMTEJ5Y2xYLTI5WDY0cExJV19RZWsyMDFSSVVRME9pQ1kzYUdTamdPYVlYdllxMHluQlA5Si02THJLaXJZOF9SRzNxdUJ0dTlic2haTlVPRy1TU2ZtdG9uY25FR0t2VEJSTzZjSGFqTzJ3ckpzOHdKbXRIZHhlT25RZGd6RnluMjU4WWV0TmJRSUZjQXVjQlRScExCblZsZ2V4RmE2?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PepGen stock slides on FDA partial hold (PEPG:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5yNUhlRWwtVDZiVmRQeHAzeFMxWkdUT2E3cEJZSUhqSWtLMk1FWWw3Z09VUjUwMGYzM0JhVVg3Y0R5OWtQMVdraEdhbGdHTldvUy1fWVhpdUxGaUw1T29mZE5DWUxBQXVkRDRjVC1wVjdEUG5nQkswTmZISklRS1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen stock plunges 26% on FDA partial clinical hold", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNcTR1UW02Zjg3cTNoUHJYa3Q2b2huZWtaMlMyUkFkejd1dmJLRFAxNGNQZVJ2SE9jWnlWeUtSMEZwYXJIR2xmQ3daTWhVWDJIN1BxUjI1andfSW9LVHFCQ2V2U0xORHRUcW81WVliMWRzMkpMa0JzYzNGbnpSYzQ2THFWU3VPWEtkX0JOQ0pvZzRwelJTTlBhMVlQUjVROVk1OHIteVU1T25vZElmVWJMM1czUzQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US pause, overseas dosing: PepGen trial tests new DM1 treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOMlpjMENJSUd5TzVxWHVDMVlCbFB1Vllrek5HWktscVYyZWN5MWVIQUp5d01QTEp4TDBRNWNHNVpzVFNaZVZMV25EQ1E4cV92M0JGLXFEUUJmbUxwcUowZVFLbDM5SWplTHN1SXNFOUw0Wlh3MmVZMXJWUDA0RTF2YkFUUGoxUjQ1Yy13ZlhtYnRaQmppbXFOUlhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNYTRGM0dTRlQzUkdhTFZva1JoWllmOGpPanVicGxZTnlVeWNNRWxCZF9INE93YzZFTTR4b3N3VUptQWo0bm9KVU1iUEVidExNUWxKdTViTjZKa0VwYkRtQlNSZVlDeTFaRkw3NVl2QVg0R1dhUjBXb2MwNmtmUm8tLVRWeS04dU5UVG0teDZNQ1pJTHVFbzhYUDlmd0FkVFAyY2ZwSUhyS0RUZ3p1Z1hRNmlDWVUwODJQYWUyYml2MTNUYW5vd0wxMWU0TmFxdWtpSGdQVzYyUdIB3AFBVV95cUxNUy05cWRqaDh2c0ZLRUNsWWlzQUFSNzRIaUREcWtnZm9fR1Y2elJUV3NDbklLdHdKVXNRbVBkbHM4VVhDNmdlMEViUHpYYW1VQ1pybjlFQ2IwRGp6a0k0LXhNdm9VTXM4cXJWSjFwLWs1bTRQbUwwZUZnQVJQRnJLb0NVLVBKa1dfVjBlbWw2em4wWW1CdEFxOWw2Y2JFdV9qNmVVLVlLcjU5WUN6ZEtfOElyVXBmVXRNVk11aVNTTVQ3T0pBeUlITVlpRVlQSnNsZ3lPdmRPNk9PamRz?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPGEN INC. (NASDAQ: PEPG) SHAREHOLDER ALERT: Bernstein", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxQX0pYR2paSE1mdkNvanNHZHZna05MTmFmazhCdTJsc3VkOGpxSkVJaXNaNnpyMC10YkZRMVYwMmxWMDlwMFdBRU1SeHNiTV8zeTR1VmJ2X0s5cE9DVVN2djJ6UjJ4VDdBamJHZ0lPalpqNGJzdnRkMWNVNDFrVTVQZGIwWm0zVVM0OXZabjJCakZacTZTTWlEOGxwWm5ja0Z4SjlzTThhMGRCdWlwbjJXdUJabWNWMmdFMHZZOHJsSFRERkVPMjhMQUcxVVZsN25FSVduUWNldnZMNjdocEhFY3UzOXFJaENFeF9GWTRLUlJldkdRMHZDa2tkUG8wYURkeUFOLVlrZDdyRVN6c0Eyd284QQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-06-30T07:00:00+00:00", "published_display": "30 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxON2g0OW5WZlpUZHVxWWRCSWY3TmtEM2QtZzNzenhST09wSUJqZEdvYm1KaXJHWndmbHh3ajVIcDZGUVltaW0tczF0MGdreDBHVmRqTWZsaG4zcFdZd0NaY2lkRlNKbFo5aHRtNmNZZXpQNVE0bGl0QW11bUdwRmU5QWFlRzdmZmVNSGZYWWp5SzNpQktjclRpQ1pKQThXeFp6VWliOXhsdGhzdzhUQ1hQVmlMTW45dVNWamFydGFpU0JyYXRjOC1nWW01eTdleTJCemQ5UU9nOWdNLXZmQTU3ZTJLcGQ4UWh5SDJVNDJRank?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-22T07:00:00+00:00", "published_display": "22 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAJBVV95cUxPazdONVBJdENoQl9iOTBpNGRiS1BKMUh1b2N3NS1hcDN2UzQ1ODVrM1FUVW5UZ0hUVkFEdmFoNVo3ak90UG9UUHMwVk1RSlMwMlNKTTJBeEdQa0RTOFA3Tm1fd1ZEU256dmw5VFdaMmNQRHM2U0p4WnB6a0VESlN3cTh6d2d5bE1vckRkNGpOYnhLNklvYWZ4RTRhUk9MRWpHSW9OeERBWG9kQU05Y3lvUVJxeGt5T1hUZ0xrQ0h0WGxUbXFMUVdrY2s3anFQd2lDdmRMRGxWYmQxWEhnVkhoWjdYZ05tdVpPamphYkpWZjExMXc2TXJiUktGOHZHUzc0MXZXR3h3WXBxcHRYbjBZMkotcDBERXNtTWNhbEdpYlJHYWc1QWxzOHAxQ3RkMGdiSF9JbHNMNlNMdm5aeFFuU1BGbjkza29O?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-06-11T07:00:00+00:00", "published_display": "11 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE05TTJpU3JBSU1ZazdYaFpOeWZBcV8zZVBOdHp6RUFpMmVMWmk5cV9JSExuaktDZUxXS19lR2w5M003VWVSSzVOdV9Hb2VKTUFRbklV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:56:41+00:00", "published_display": "25 Apr 2025 00:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Pauses PepGen\u2019s DMD Drug Trial in the US", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTFBMeHFicThPWE1xRUNQOUd3S0s1eld6UnVMNjZGZFdRc1NkRVBWTkd0SUVQMGlvSjI5NWxpMW1weFRPWXpKclpVdTBzWVF2WXgtSHNKY0pqNEtKVlNGWkJjdlUxck5YV2RGblNIUVRna0p2Zk9BS2czV05R?oc=5", "source_name": "The American Journal of Managed Care\u00ae (AJMC\u00ae)", "published_at": "2024-12-19T08:00:00+00:00", "published_display": "19 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "PEPG - PepGen Inc Latest SEC Filings", "summary": "This page provides the latest SEC filings for PepGen Inc. (PEPG), along with a comprehensive overview of its financial performance, stock statistics, and trading data. It includes key metrics such as market capitalization, income, sales, EPS, insider and institutional ownership, ", "url": "https://finviz.com/stock?t=PEPG&p=m&ty=lf&b=2&r=max&page=2", "source_name": "Finviz", "published_at": "2026-07-04T19:10:29", "published_display": "04 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPG LAWSUIT ALERT: Levi & Korsinsky Notifies PepGen Inc. Investors - Lead Plaintiff Deadline August 8, 2025", "summary": "Levi & Korsinsky LLP has issued a lawsuit alert for investors of PepGen Inc. (NASDAQ: PEPG) who suffered losses. The class action securities lawsuit alleges that PepGen made false statements regarding the effectiveness and safety of its lead product candidate, PGN-EDO51, and its ", "url": "https://www.natlawreview.com/press-releases/pepg-lawsuit-alert-levi-korsinsky-notifies-pepgen-inc-investors-lead", "source_name": "The National Law Review", "published_at": "2026-07-03T05:39:57", "published_display": "03 Jul 2026 05:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages PepGen Inc. (PEPG) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of PepGen Inc. (PEPG) investors who purchased securities prior to March 7, 2024, and continue to hold them. The investigation aims to determine if PepGen and its officers/directors engaged in corporate", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-pepgen-inc-pepg-investors-inquire", "source_name": "The National Law Review", "published_at": "2026-07-02T07:40:51", "published_display": "02 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of PepGen Inc. \u2013 NASDAQ:PEPG", "summary": "This page from TradingView provides financial information for PepGen Inc. (NASDAQ: PEPG), specifically focusing on its \"Price to book forward\" metric. It appears to be an empty or placeholder financial data point for the specified period.", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T09:12:32", "published_display": "01 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by PepGen Inc. (NASDAQ: PEPG). The firm encourages shareholders who purchased PepGen securities before March 7, 2024, and still hold them, to contact them to learn more and potent", "url": "https://natlawreview.com/press-releases/pepgen-inc-pepg-investigation-bronstein-gewirtz-grossman-llc-encourages-0", "source_name": "The National Law Review", "published_at": "2026-06-29T16:39:45", "published_display": "29 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of PepGen Inc. \u2013 NASDAQ:PEPG", "summary": "This article displays the Enterprise Value to EBIT forward for PepGen Inc. (NASDAQ: PEPG). The content primarily consists of navigation and boilerplate information from the TradingView platform, with the specific financial data point \"Enterprise value to EBIT forward\" listed for ", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T17:10:19", "published_display": "28 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating PepGen Inc. (PEPG) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against PepGen Inc. (PEPG) for alleged corporate wrongdoing. The investigation encourages stockholders who purchased PepGen securities before March 7, 2024, and still hold them, to contact the firm to assist wit", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-pepgen-inc-pepg-and-encourages", "source_name": "The National Law Review", "published_at": "2026-06-28T16:39:02", "published_display": "28 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed: PepGen Inc. (PEPG) - Join by August 8, 2025 - Contact Levi & Korsinsky", "summary": "A class action lawsuit has been filed against PepGen Inc. (NASDAQ:PEPG) alleging securities fraud between March 7, 2024, and March 3, 2025. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky, LLP by August 8, 2025, to learn about their ", "url": "https://www.natlawreview.com/press-releases/class-action-lawsuit-filed-pepgen-inc-pepg-join-august-8-2025-contact-levi", "source_name": "The National Law Review", "published_at": "2026-06-28T04:10:38", "published_display": "28 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PepGen Inc. \u2013 NASDAQ:PEPG", "summary": "The article focuses on the \"Price to sales forward\" metric for PepGen Inc. (NASDAQ: PEPG). It indicates that the financial data is provided by ICE Data Services and FactSet Research Systems Inc., with SEC filings by Quartr. The content appears to be a financial data point within ", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:10:26", "published_display": "28 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of PepGen Inc. \u2013 BOATS:PEPG", "summary": "This article provides financial information for PepGen Inc. (PEPG) on the Blue Ocean Alternative Trade System (BOATS). It specifically focuses on the company's price to earnings forward ratio, indicating financial data for the period, value, change, and change percentage.", "url": "https://www.tradingview.com/symbols/BOATS-PEPG/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T01:09:26", "published_display": "28 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPG SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against PepGen Inc. (NASDAQ: PEPG). The lawsuit alleges that PepGen and its officers made false and misleading statements about the effectiveness and safety of PGN-EDO51 and the CONNECT2 study, which overstat", "url": "https://natlawreview.com/press-releases/pepg-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-pepgen-1", "source_name": "The National Law Review", "published_at": "2026-06-27T15:10:26", "published_display": "27 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did You Lose Money on PepGen Inc. (PEPG)? Levi & Korsinsky Urges Investors to Act Before August 8, 2025", "summary": "Levi & Korsinsky LLP is urging investors of PepGen Inc. (PEPG) who suffered losses to act before August 8, 2025, to potentially recover losses through a class action securities lawsuit. The lawsuit alleges that PepGen made false statements regarding its lead product candidate, PG", "url": "https://natlawreview.com/press-releases/did-you-lose-money-pepgen-inc-pepg-levi-korsinsky-urges-investors-act-august", "source_name": "The National Law Review", "published_at": "2026-06-27T14:09:26", "published_display": "27 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of PepGen Inc. \u2013 NASDAQ:PEPG", "summary": "This article focuses on shareholder information for PepGen Inc. (NASDAQ: PEPG). It provides access to financial data, news, documents, and community discussions related to the company on the TradingView platform. Users can find details about the number of shareholders over differ", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-27T11:38:42", "published_display": "27 Jun 2026 11:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of PepGen Inc. \u2013 BOATS:PEPG", "summary": "This article provides the forward price-to-sales ratio for PepGen Inc. (PEPG). It presents a financial data point for the company and is hosted on TradingView, a financial charting and analysis platform.", "url": "https://www.tradingview.com/symbols/BOATS-PEPG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:38:42", "published_display": "27 Jun 2026 10:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc. Actuals & Estimates (NASDAQ:PEPG)", "summary": "This article provides an overview of PepGen Inc. (NASDAQ:PEPG) financial actuals and estimates, including its current stock price, historical performance, analyst forecasts, and company financials. It details the company's stock volatility, market capitalization, earnings per sha", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:09", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for PepGen Inc. (PEPG), based on analyst opinions. It includes current stock performance, historical highs and lows, volatility, market capitalization, and details on earnings and revenue. The report also addresses frequently aske", "url": "https://www.tradingview.com/symbols/NASDAQ-PEPG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:23", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) director granted 34,000 options for RA Capital funds", "summary": "PepGen Inc. director Joshua Resnick was granted 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. These options are held for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account, with Resnic", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-c4c5164d10fc.html", "source_name": "Stock Titan", "published_at": "2026-06-23T15:10:26", "published_display": "23 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) awards director 34,000 options vesting by next meeting", "summary": "PepGen Inc. (PEPG) reported that director Lisa Wyman received a grant of 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. These options will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-73a63580950b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T13:40:23", "published_display": "23 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "34K PepGen (PEPG) options awarded for RA Capital-managed accounts", "summary": "PepGen Inc. reported a compensation-related transaction where an option to purchase 34,000 shares of common stock was awarded to Dr. Resnick, a director, for the benefit of RA Capital-managed entities. The option has an exercise price of $1.79 per share and vests fully upon the e", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-805a19cec65f.html", "source_name": "Stock Titan", "published_at": "2026-06-23T03:09:26", "published_display": "23 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen director granted options for 34,000 shares | PEPG Insider Trading", "summary": "PepGen Inc. director Laurie Keating was granted stock options for 34,000 shares at an exercise price of $1.79 per share, expiring on June 17, 2036. The options will vest fully on the earlier of the first anniversary of the grant date or the next Annual Meeting, provided she conti", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-231dc1448654.html", "source_name": "Stock Titan", "published_at": "2026-06-23T01:09:13", "published_display": "23 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) director receives 34,000 stock options at $1.79 strike", "summary": "PepGen Inc. director Mitchell H. Finer was granted 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. The options vest fully on the earlier of the first anniversary of the grant date or the next Annual Meeting, provided he continues to serv", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-7a427c8d17ea.html", "source_name": "Stock Titan", "published_at": "2026-06-23T01:09:13", "published_display": "23 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) loses 14.3% in 4 weeks, here's why a trend reversal may be around the corner", "summary": "The article suggests PepGen (PEPG) stock, which has fallen 14.3% in the last four weeks, might be due for a trend reversal. This potential shift is based on the company's strong fundamentals and the stock's current oversold condition, as indicated by its 10-day moving average and", "url": "http://www.msn.com/en-us/money/top-stocks/pepgen-pepg-loses-14-3-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner/ar-AA23F6Wo?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-23T00:40:38", "published_display": "23 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 PepGen Ltd For: 22 June By Investing.com", "summary": "This article announces the filing of Form 4 for PepGen Ltd. on June 22 and provides a link to view the filing. It also includes general market data and related news without further details on the specific Form 4 content.", "url": "https://ng.investing.com/news/stock-market-news/form-4-pepgen-ltd-for-22-june-93CH-2568525", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T21:10:00", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) investors elect Class I directors and ratify KPMG as 2026 auditor", "summary": "PepGen Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026, where shareholders elected three Class I directors: Howard Mayer, M.D., Joshua Resnick, M.D., M.B.A., and Lisa Wyman, M.S. These directors will serve until the 2029 annual meeting. Shareholders also ratifi", "url": "https://www.stocktitan.net/sec-filings/PEPG/8-k-pep-gen-inc-reports-material-event-37f2b5748084.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:49", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) director Howard Mayer awarded options on 34,000 shares", "summary": "PepGen Inc. director Howard Mayer was granted 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. This grant is part of his compensation and vests fully on the earlier of the first anniversary of the grant date or the next annual meeting, pr", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-1f8837eb19c2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:39:49", "published_display": "22 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) director receives 34,000 stock options grant", "summary": "PepGen Inc. director Heidi Henson was granted 34,000 stock options with an exercise price of $1.79 per share, expiring on June 17, 2036. These options will vest fully on the earlier of the first anniversary of the grant date or the next Annual Meeting, subject to her continued se", "url": "https://www.stocktitan.net/sec-filings/PEPG/form-4-pep-gen-inc-insider-trading-activity-3653eeff10c0.html", "source_name": "Stock Titan", "published_at": "2026-06-22T19:39:49", "published_display": "22 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc (PEPG) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of PepGen Inc (PEPG), identifying major individual shareholders like RA Capital Management, LP and Oxford Science Enterprises PLC, along with their respective proportions. It also categorizes shareholders by type, such as venture cap", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pepg/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:05", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc (PEPG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for PepGen Inc (PEPG), highlighting analyst ratings, target prices, and revenue growth estimates. Seven analysts currently rate the stock as \"Buy,\" with a target price of $9.00 and an upside potential of 537.92%. The article also reviews", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pepg/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:05", "published_display": "18 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum initiates PepGen stock coverage with buy rating By Investing.com", "summary": "Craig-Hallum has initiated coverage on PepGen Inc. (NASDAQ:PEPG) with a buy rating and an $11.00 price target, noting a substantial upside potential from its current trading price of $1.64. The firm sees PepGen's lead drug candidate, PGN-EDODM1, as a high-risk but highly asymmetr", "url": "https://za.investing.com/news/stock-market-news/craighallum-initiates-pepgen-stock-coverage-with-buy-rating-93CH-4330937", "source_name": "Investing.com South Africa", "published_at": "2026-06-17T12:13:15", "published_display": "17 Jun 2026 12:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Initiates PepGen at Buy With $11 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/craig-hallum-initiates-pepgen-buy-112120380.html", "source_name": "MT Newswires", "published_at": "2026-06-16T11:21:20+00:00", "published_display": "16 Jun 2026 11:21", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] PepGen Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPcllrU0NLdmhYaXhoUjhXMEZYTmlJSThScXJHc1JkbGFFSk1tZmVIVTA1OGN3ajVfSW1FdVdqclFMV05zMXJIZ0Uxa0FBOGhfQXMxZ3d3eG83YWw4aERKWHdBRjdVTmZ5R0ZsSTF1LUM2NWtrZHQ2YTUwOU1CT19NYnJneERjdDc2R09DVlVZeS1WVVNWdXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Files $400 Million Mixed Shelf", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/pepgen-files-400-million-mixed-162328424.html", "source_name": "MT Newswires", "published_at": "2026-05-19T16:23:28+00:00", "published_display": "19 May 2026 16:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPT2c3djRxN1oyeW85V0hCN2JJS0h4UW9pd3ZSa3AzS2xyUG04SkQ2M2FHTktuVVVlREN6Z1BUMXJRN0lrWmVtQW5LOTNWVzZWY1FzU2lXLU00SUl2a25nbjRMOXhib2lYSEc0ZmJpZFVrVmt5QkpnQ0JxWHdvdkI1YkoxZWhpMHhmeXdHbGdDel9RTlYzMzhN?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/news/pepgen-pepg-upgraded-buy-heres-160004314.html", "source_name": "Zacks", "published_at": "2026-05-13T16:00:04+00:00", "published_display": "13 May 2026 16:00", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Trims Price Target on PepGen to $4 From $5, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/news/wedbush-trims-price-target-pepgen-132631278.html", "source_name": "MT Newswires", "published_at": "2026-05-13T13:26:31+00:00", "published_display": "13 May 2026 13:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPVGZHaHJGVHZLa1RoMHByRFlJZHFnNHZ6QzRrMWFURUZZWC10QXlXWTlNc0RPUGVGWXZOSkZqWlV0M2JDMkR0dUJVVUlOVm52N0pGaEZWMWVTMUJ5Ulh1ckt3QTlrVkdZU19MaHlnc0RpSFhSUE52azY3bEp5NDRGRmdIM3k2Wm55TlBZT1UtTERqaHpPb1YtSjl5aEgycW5ZMlhRRzREZFhCdTNtckwwY1M4TXJ2SXRPWkRVMUZXd044MTI4VU1zUkJwT1BxcEZMU0QyOFR2ZjZjdFFlSV8yazRmR1ZTQTBN?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At PepGen (PEPG) Valuation After FREEDOM2 Phase 2 Topline Update", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQOUhEOFRqdjlfYU1aZ0plVm9xd2tSd0ZsTXJjZnp0YVUxR3VUQzBZRE95eG9EQnlkUDg4U0VERVRGM1NjVkc5NFJ5Y0JJczI0RXJQdHBHOGZaRkwwa01nZHlBVTUtSU5VWnJ1alg4c3ZkN3NEeUN2LTNnVkhPWmlqX3pxNzlPbmVISWwzMUFkNnhzTnNYWTN4NFg3TVNzLTRCSHhTNFFLWmNGV2ZjVEdLOWVRbzB1Znhr?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen Inc. Shareholders Are Encouraged to Reach Out to", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxNZlZnaDVsQ1owbmQzcGpkdGtrVDROSFJmVWhSa0xGSUNMdzMteHFObXdOLUlmVHdrSlJmbXp1QXlaWGMtOU1SS0NST0w4aXppQllHR2hfYzNjVXB5ekVLdlU4MWhxaEJSbUMxal92YzhxeVBxYzBVb2lxMFFkTGowZUdqRGVHSGVjZmpYbEhaNUpBcjhVUGZPeE5ELXFPRzZJU1BIQ2xrM2FvVW96YXhwOG9YZ3N2QTh3SmItQk1xNnV1ZGxmOGJXS1ZKdUVSUDhUVGhjVHltR3dxMmlnamRyMDItcFZjX0NibkpQUFVtSm9GZUtxc3hJTWRZWlJHaFFhOEhlWUpISElPcXNQUlhITjE3b2tRNjlQakZaRWNqNXkyeWRJS3RvU2t0cw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQbzNUVFBsMk9odF9DWUpQTi0zUDNqNnFTa0FuZXNGdXBVUGhZVTZLX014NDFBWEJaRkJQY1hmSldFZWVGUkVQei02dGp6ajZJV2d2Q21hR0MzenlmWTFkWjI2WXh5Z25IWXp4anZmZW9nQmJTNHFsM3Vxd190R2dqOHJpaTkzbVQySEE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In an 8-patient muscle disease study, PepGen saw no serious safety issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOdGxTN1Bwc0Q0WHlyRk41Z1hZNnpMTEJ5Y2xYLTI5WDY0cExJV19RZWsyMDFSSVVRME9pQ1kzYUdTamdPYVlYdllxMHluQlA5Si02THJLaXJZOF9SRzNxdUJ0dTlic2haTlVPRy1TU2ZtdG9uY25FR0t2VEJSTzZjSGFqTzJ3ckpzOHdKbXRIZHhlT25RZGd6RnluMjU4WWV0TmJRSUZjQXVjQlRScExCblZsZ2V4RmE2?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen stock slides on FDA partial hold (PEPG:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5yNUhlRWwtVDZiVmRQeHAzeFMxWkdUT2E3cEJZSUhqSWtLMk1FWWw3Z09VUjUwMGYzM0JhVVg3Y0R5OWtQMVdraEdhbGdHTldvUy1fWVhpdUxGaUw1T29mZE5DWUxBQXVkRDRjVC1wVjdEUG5nQkswTmZISklRS1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen stock plunges 26% on FDA partial clinical hold", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNcTR1UW02Zjg3cTNoUHJYa3Q2b2huZWtaMlMyUkFkejd1dmJLRFAxNGNQZVJ2SE9jWnlWeUtSMEZwYXJIR2xmQ3daTWhVWDJIN1BxUjI1andfSW9LVHFCQ2V2U0xORHRUcW81WVliMWRzMkpMa0JzYzNGbnpSYzQ2THFWU3VPWEtkX0JOQ0pvZzRwelJTTlBhMVlQUjVROVk1OHIteVU1T25vZElmVWJMM1czUzQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US pause, overseas dosing: PepGen trial tests new DM1 treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOMlpjMENJSUd5TzVxWHVDMVlCbFB1Vllrek5HWktscVYyZWN5MWVIQUp5d01QTEp4TDBRNWNHNVpzVFNaZVZMV25EQ1E4cV92M0JGLXFEUUJmbUxwcUowZVFLbDM5SWplTHN1SXNFOUw0Wlh3MmVZMXJWUDA0RTF2YkFUUGoxUjQ1Yy13ZlhtYnRaQmppbXFOUlhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPGEN INC. (NASDAQ: PEPG) SHAREHOLDER ALERT: Bernstein", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxQX0pYR2paSE1mdkNvanNHZHZna05MTmFmazhCdTJsc3VkOGpxSkVJaXNaNnpyMC10YkZRMVYwMmxWMDlwMFdBRU1SeHNiTV8zeTR1VmJ2X0s5cE9DVVN2djJ6UjJ4VDdBamJHZ0lPalpqNGJzdnRkMWNVNDFrVTVQZGIwWm0zVVM0OXZabjJCakZacTZTTWlEOGxwWm5ja0Z4SjlzTThhMGRCdWlwbjJXdUJabWNWMmdFMHZZOHJsSFRERkVPMjhMQUcxVVZsN25FSVduUWNldnZMNjdocEhFY3UzOXFJaENFeF9GWTRLUlJldkdRMHZDa2tkUG8wYURkeUFOLVlrZDdyRVN6c0Eyd284QQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-06-30T07:00:00+00:00", "published_display": "30 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxON2g0OW5WZlpUZHVxWWRCSWY3TmtEM2QtZzNzenhST09wSUJqZEdvYm1KaXJHWndmbHh3ajVIcDZGUVltaW0tczF0MGdreDBHVmRqTWZsaG4zcFdZd0NaY2lkRlNKbFo5aHRtNmNZZXpQNVE0bGl0QW11bUdwRmU5QWFlRzdmZmVNSGZYWWp5SzNpQktjclRpQ1pKQThXeFp6VWliOXhsdGhzdzhUQ1hQVmlMTW45dVNWamFydGFpU0JyYXRjOC1nWW01eTdleTJCemQ5UU9nOWdNLXZmQTU3ZTJLcGQ4UWh5SDJVNDJRank?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-22T07:00:00+00:00", "published_display": "22 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PEPGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAJBVV95cUxPazdONVBJdENoQl9iOTBpNGRiS1BKMUh1b2N3NS1hcDN2UzQ1ODVrM1FUVW5UZ0hUVkFEdmFoNVo3ak90UG9UUHMwVk1RSlMwMlNKTTJBeEdQa0RTOFA3Tm1fd1ZEU256dmw5VFdaMmNQRHM2U0p4WnB6a0VESlN3cTh6d2d5bE1vckRkNGpOYnhLNklvYWZ4RTRhUk9MRWpHSW9OeERBWG9kQU05Y3lvUVJxeGt5T1hUZ0xrQ0h0WGxUbXFMUVdrY2s3anFQd2lDdmRMRGxWYmQxWEhnVkhoWjdYZ05tdVpPamphYkpWZjExMXc2TXJiUktGOHZHUzc0MXZXR3h3WXBxcHRYbjBZMkotcDBERXNtTWNhbEdpYlJHYWc1QWxzOHAxQ3RkMGdiSF9JbHNMNlNMdm5aeFFuU1BGbjkza29O?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-06-11T07:00:00+00:00", "published_display": "11 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PepGen (PEPG) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE05TTJpU3JBSU1ZazdYaFpOeWZBcV8zZVBOdHp6RUFpMmVMWmk5cV9JSExuaktDZUxXS19lR2w5M003VWVSSzVOdV9Hb2VKTUFRbklV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:56:41+00:00", "published_display": "25 Apr 2025 00:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Pauses PepGen\u2019s DMD Drug Trial in the US", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTFBMeHFicThPWE1xRUNQOUd3S0s1eld6UnVMNjZGZFdRc1NkRVBWTkd0SUVQMGlvSjI5NWxpMW1weFRPWXpKclpVdTBzWVF2WXgtSHNKY0pqNEtKVlNGWkJjdlUxck5YV2RGblNIUVRna0p2Zk9BS2czV05R?oc=5", "source_name": "The American Journal of Managed Care\u00ae (AJMC\u00ae)", "published_at": "2024-12-19T08:00:00+00:00", "published_display": "19 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 59, "sentiment_summary": {"positive": 10, "negative": 8, "neutral": 41, "score": 48, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 19.75, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 2.55, "count": 4}], "positive_events": 10, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 2.34, "latest_week": "2026-07-10", "one_week_move": 33.0, "four_week_move": 59.2, "twelve_week_move": 37.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.204239, "market_dynamics_buy_signal": false, "relative_strength": -44.191703, "fair_value_gap": -61.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.2547, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+33.0% over one week, +59.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "TradingView", "count": 9}, {"label": "The National Law Review", "count": 7}, {"label": "Market source", "count": 6}, {"label": "simplywall.st", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Seeking Alpha", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 14}, {"label": "Regulatory and legal", "count": 7}, {"label": "Analyst action", "count": 4}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+33.0% over one week, +59.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "PEPG - PepGen Inc Latest SEC Filings"}], "updated_at": "2026-07-16T22:50:22.189429+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}